Biora Therapeutics, Inc.
BIORQ
$0.00
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 15,800.00% | 27,000.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 15,800.00% | 27,000.00% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 15,800.00% | 27,000.00% | -- | -- |
| SG&A Expenses | -16.64% | -6.18% | 8.34% | -9.93% | 56.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -30.28% | 7.82% | 3.29% | -3.23% | 66.97% |
| Operating Income | 30.42% | -5.71% | 0.18% | 3.14% | -67.93% |
| Income Before Tax | 69.69% | 135.94% | 76.26% | -19.05% | -399.14% |
| Income Tax Expenses | -4,500.00% | -1,775.00% | -- | -136.68% | -99.37% |
| Earnings from Continuing Operations | 69.75% | 136.31% | 75.98% | -16.06% | -393.84% |
| Earnings from Discontinued Operations | -- | -- | -- | 186.56% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.95% | 136.31% | 75.98% | -12.32% | -1,336.33% |
| EBIT | 30.42% | -5.71% | 0.18% | 3.14% | -67.93% |
| EBITDA | 30.52% | -6.15% | -0.09% | 2.93% | -69.50% |
| EPS Basic | 89.70% | 112.34% | 91.01% | 62.20% | -614.89% |
| Normalized Basic EPS | 76.52% | 112.22% | 91.47% | 49.42% | 31.49% |
| EPS Diluted | 89.70% | 97.59% | 91.01% | 62.24% | -613.87% |
| Normalized Diluted EPS | 76.52% | 105.88% | 91.47% | 49.42% | 31.49% |
| Average Basic Shares Outstanding | 143.12% | 194.16% | 167.04% | 197.14% | 100.92% |
| Average Diluted Shares Outstanding | 143.12% | 511.18% | 167.04% | 197.14% | 100.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |